GlassScriptPhysician profile
Bradley C Sevy
NPI 1437530896
$1,362.78
in general payments reported to CMS, 2019-2025
15 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $11.72 · 2021: $15.34 · 2023: $23.67 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $256.34 | 2019-2025 | Wegovy |
| Amgen INC. | $215.03 | 2019-2025 | Repatha, Otezla |
| Abbvie INC. | $202.74 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.04 | 2025 | |
| Exact Sciences Corporation | $125.96 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $85.02 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.11 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $51.32 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.57 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $49.14 | 2019-2025 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $44.87 | 2025 | Breztri, Farxiga |
| Inspire Medical Systems, INC. | $22.71 | 2025 | Inspire |
| Dexcom, INC. | $22.31 | 2025 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $19.92 | 2025 | Fanapt |
| Abbott Laboratories | $19.70 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Sevy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.